When should oral naltrexone be held before spine surgery, and what is the recommended timing for the extended‑release injectable formulation (Vivitrol, naltrexone)?

When to Hold Naltrexone for Spine Surgery

For oral naltrexone, hold for 2–3 days before spine surgery; for extended-release injectable naltrexone (Vivitrol), hold for 24–30 days after the last injection if opioids are expected to be used perioperatively. 1

Oral Naltrexone Timing

• Discontinue oral naltrexone 2–3 days (48–72 hours) prior to elective spine surgery when postoperative opioid analgesia is anticipated 1, 2, 1
• The plasma half-life of naltrexone is 4 hours, but its active metabolite (6-β-naltrexol) has a half-life of 13 hours and accumulates during chronic therapy 1
• Antagonist effects may persist for 2–3 days after stopping due to metabolite accumulation, which is why this holding period is necessary 1

Extended-Release Injectable Naltrexone (Vivitrol) Timing

• Hold extended-release naltrexone for 24–30 days after the last intramuscular injection before elective spine surgery if opioids will be needed 1
• The elimination half-life of Vivitrol is 5–10 days and depends on polymer erosion, with measurable levels persisting for greater than 1 month 3
• Patients on extended-release naltrexone may have upregulated opioid receptors from long-term maintenance therapy, potentially making them refractory to opioid effects or paradoxically more sensitive to dangerous side effects 1, 4
• Concentrations slowly decline beginning approximately 14 days after dosing, but the extended duration of action necessitates the longer holding period 3

Critical Perioperative Considerations

Anesthesia Team Communication

• Inform the anesthesiologist of naltrexone use, formulation (oral vs. injectable), last dose timing, and indication (alcohol use disorder vs. opioid use disorder) 1
• If naltrexone was not held appropriately, expect higher-than-normal opioid doses to be required for adequate analgesia, and anticipate potential failure of standard opioid dosing 4

Multimodal Analgesia Planning

• Implement aggressive multimodal analgesia strategies including regional anesthesia techniques, NSAIDs, acetaminophen, ketamine, and gabapentinoids to minimize opioid requirements 2, 5
• Even with appropriate holding periods, patients may require higher opioid doses due to receptor changes from chronic naltrexone exposure 5, 4

Risk of Precipitated Withdrawal

• Do not restart naltrexone until all opioid use has ceased and adequate time has passed to avoid precipitating severe opioid withdrawal 1, 3
• Redosing naltrexone soon after opioid use can precipitate acute withdrawal symptoms that may be severe enough to require hospitalization 3, 4

Common Pitfalls to Avoid

• Do not assume 12 hours is sufficient for oral naltrexone discontinuation, as one case report demonstrated inadequate pain control despite stopping 12 hours preoperatively 5
• Do not confuse naltrexone with naloxone: naloxone has a much shorter duration (45 minutes to 4 hours depending on route) and only requires awareness if given within 4 hours preoperatively 1
• Do not restart naltrexone in the immediate postoperative period while the patient still requires opioid analgesia, as this will block analgesic efficacy and may precipitate withdrawal 1, 4
• Do not use long-acting opioid formulations (extended-release tablets or transdermal patches) for postoperative pain in these patients, as they increase risk and provide no benefit 6

Special Populations

Patients with Substance Use Disorders

• For patients taking naltrexone for opioid or alcohol use disorder, coordinate with their addiction medicine provider before discontinuing to develop a comprehensive perioperative plan 2
• Ensure access to opioid overdose reversal agents (naloxone) at discharge, as patients may be at increased risk for overdose after naltrexone discontinuation due to loss of tolerance 3

Emergency Surgery

• When spine surgery cannot be delayed for appropriate naltrexone washout, expect opioid resistance and plan for significantly higher opioid doses, alternative analgesic strategies, and potential use of partial agonists 4
• Consider ketamine infusions, regional techniques, and non-opioid adjuncts as primary analgesic modalities 5, 4